# Lovastatin for Treatment of Brain Arteriovenous Malformations

Study · id `cardio:ct-nct04297033` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04297033](<https://clinicaltrials.gov/study/NCT04297033>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT04297033

Browse, organ or system: Blood vessels; Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1244 participants.

## Technical summary

Registry record NCT04297033. Randomized; double masking; primary purpose treatment. Start 2021-01-01 (anticipated); primary completion 2024-06-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 1244 participants (planned count; ClinicalTrials.gov record NCT04297033, source copy `cardio:ctgov-nct04297033-2020-03-09`, retrieved 2026-11-18)
- Planned start: 2021-01-01 (anticipated) (ClinicalTrials.gov record NCT04297033, source copy `cardio:ctgov-nct04297033-2020-03-09`, retrieved 2026-11-18)
- Primary completion: 2024-06-01 (anticipated) (ClinicalTrials.gov record NCT04297033, source copy `cardio:ctgov-nct04297033-2020-03-09`, retrieved 2026-11-18)
- Completion: 2024-06-01 (anticipated) (ClinicalTrials.gov record NCT04297033, source copy `cardio:ctgov-nct04297033-2020-03-09`, retrieved 2026-11-18)
- Countries: China (ClinicalTrials.gov record NCT04297033, source copy `cardio:ctgov-nct04297033-2020-03-09`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04297033-2020-03-09`, retrieved 2026-11-18)

## The registry's words

- Brief title: Lovastatin for Treatment of Brain Arteriovenous Malformations
- Condition: Cerebral Arteriovenous Malformation
- Intervention (Drug): Lovastatin
- Intervention (Drug): Placebo
- Lead sponsor: Beijing Tiantan Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arteriovenous malformation (AVM) (`cardio:arteriovenous-malformation`)
- Registry lists this organization as the lead sponsor: Beijing Tiantan Hospital (`cardio:org-beijing-tiantan-hospital`)

## Provenance

Content hash: 6e306faed7a80de079709779386f60efb8e6005457002e5d6319d8a1af0cc186
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
